Aptamer Group (AIM:APTA) expects to report revenue of approximately £1.5 million for the year ended 30 June, up 25% on the £1.2 million reported the prior year.
The AIM-listed developer of synthetic Optimer binders, used in diagnostics and drug discovery, said growth came from increased fee-for-service activity and initial contributions from its first licensing agreements.
The sales pipeline rose 55% to £4.8 million from £3.1 million at the January half-year update, with a £0.6 million order book already contracted for FY2027.
Licensing deals signed with Twist Bioscience and Alphazyme in December 2025 generated the Group's first licensing revenues, a milestone in its push toward higher-margin income; early evaluations from a global hot-start enzyme supplier have been positive, and a further supplier has entered licensing discussions.
Operational progress included Optimer delivery to a global life sciences group under a deal carrying a 2% royalty on diagnostic kit sales, continued work on Metir plc's Cryptosporidium programme, and advancement of the Unilever skin-enzyme collaboration to on-skin testing.
Signed contracts worth approximately £769,000 with a top-five pharma partner and £190,000 with a top-ten global pharmaceutical company are progressing through Optimer selection, feeding the FY2027 order book.
"A key strategic milestone was achieved in the generation of our first licensing revenues," said Dr Arron Tolley, chief executive, adding that the Group believes it is "well positioned to continue its progress into FY2027 and beyond."
